Cart
sales@molnova.com
Homo-PROTAC pVHL30 degrader 1
CAS No. 2244684-49-7
Homo-PROTAC pVHL30 degrader 1 ( —— )
Catalog No. M24022 CAS No. 2244684-49-7
Homo-PROTAC pVHL30 degrader 1 is a potent pVHL30 degrader based on PROTAC.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 115 | In Stock |
|
| 10MG | 147 | In Stock |
|
| 25MG | 295 | In Stock |
|
| 50MG | 475 | In Stock |
|
| 100MG | 692 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHomo-PROTAC pVHL30 degrader 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionHomo-PROTAC pVHL30 degrader 1 is a potent pVHL30 degrader based on PROTAC.
-
DescriptionHomo-PROTAC pVHL30 degrader 1 is a potent pVHL30 degrader based on PROTAC.
-
Synonyms——
-
PathwayPROTACs
-
TargetE3 Ligase Ligand
-
RecptorVHL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2244684-49-7
-
Formula Weight1179.5
-
Molecular FormulaC58H82N8O14S2
-
Purity>98% (HPLC)
-
SolubilityDMSO:150 mg/mL (127.18 mM)
-
SMILESO=C(N[C@@H](C(C)(C)C)C(N1[C@H](C(NCC2=CC=C(C3=C(C)N=CS3)C=C2)=O)C[C@@H](O)C1)=O)COCCOCCOCCOCCOCCOCC(N[C@@H](C(C)(C)C)C(N4[C@H](C(NCC5=CC=C(C6=C(C)N=CS6)C=C5)=O)C[C@@H](O)C4)=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Maniaci C, et al. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. Nat Commun. 2017 Oct 10;8(1):830.
molnova catalog
related products
-
Diclone
2 ?3-?Dichloro-?1 ?4-?naphthoquinone is an inhibitor of Itch a HECT domain-E3 ligase. It is also used in pesticide formulations.
-
E3 Ligand-Linker Con...
E3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.
-
PROTAC-VHL-ligand
PROTAC-VHL-ligand is a von Hippel–Lindau (VHL) ligand used for the proteolysis targeting chimeras (PROTACs) method, induces target protein degradation.
